Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586529 | 1.00 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL11545422 | 1.00 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| Hydrochloric Acid SCHEMBL1604164 | 0.98 | CHRM5 (0.64) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| Hydrochloric Acid SCHEMBL6590070 | 0.98 | CHRM5 (0.64) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| Hydrochloric Acid SCHEMBL2674614 | 0.98 | CHRM5 (0.64) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| Hydrochloric Acid SCHEMBL8191714 | 0.98 | CHRM5 (0.64) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL11544296 | 0.98 | CHRM5 (0.62) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL11546506 | 0.93 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2OPRM1 | |
| SCHEMBL8100117 | 0.88 | CHRM5 (0.48) | CHRM5ADRA2CACHESMN1; SMN2 | |
| SCHEMBL2673448 | 0.88 | CHRM5 (0.48) | CHRM5ADRA2CACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656994-B2 | Substituted benzimidazoles as nociceptin receptor modulators | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656994-B2 | Substituted benzimidazoles as nociceptin receptor modulators | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656994-B2 | Substituted benzimidazoles as nociceptin receptor modulators | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160052913-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-02-25 | — | — | US | disclosed |
| EP-2976077-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | The Scripps Research Institute (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014153529-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153529-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-0990653-B1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-6258825-B1 | ANALGESIC, A RELIEVER AGAINST TOLERANCE TO A NARCOTIC ANALGESIC REPRESENTED BY MORPHINE, REMEDY FOR PARKINSONISM, A REMEDY FOR CHOREA, AN ANTIDEPRESSANT, A REMEDY FOR DIABETES INSIPIDUS, A REMEDY FOR POLYURIA, OR HYPOTENSION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0990653-A1 | 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052913-A1 | SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS | OPRL1, OPRK1, OPRM1 | CHRM5 60/4885ADRA2C 52/4885ACHE 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.